Skip to Content
Merck
All Photos(1)

Key Documents

EHU065181

Sigma-Aldrich

MISSION® esiRNA

targeting human FKBP10

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41105324
NACRES:
NA.51

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

GCTCTGCCGTGCTAATCTTCAACGTCCATGTCATTGACTTCCACAACCCTGCGGATGTGGTGGAAATCAGGACACTGTCCCGGCCATCTGAGACCTGCAATGAGACCACCAAGCTTGGGGACTTTGTTCGATACCATTACAACTGTTCTTTGCTGGACGGCACCCAGCTGTTCACCTCGCATGACTACGGGGCCCCCCAGGAGGCGACTCTCGGGGCCAACAAGGTGATCGAAGGCCTGGACACGGGCCTGCAGGGCATGTGTGTGGGAGAGAGGCGGCAGCTCATCGTGCCCCCGCACCTGGCCCACGGGGAGAGTGGAGCCCGGGGAGTCCCAGGCAGTGCTGTGCTGCTGTTTGAGGTGGAGCTGGTGTCCCGGGAGGATGGGCTGCCCACAGGCTACCTGTTTGTGTGGCACAAGGACCCTCCTGCCAACCTGTTTGAAGACATGGACCTCAACAAGGATGG

Ensembl | human accession no.

NCBI accession no.

shipped in

ambient

storage temp.

−20°C

Gene Information

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Larissa Knüppel et al.
Respiratory research, 19(1), 67-67 (2018-04-21)
In idiopathic pulmonary fibrosis (IPF), fibroblasts gain a more migratory phenotype and excessively secrete extracellular matrix (ECM), ultimately leading to alveolar scarring and progressive dyspnea. Here, we analyzed the effects of deficiency of FK506-binding protein 10 (FKBP10), a potential IPF
Giorgio Ramadori et al.
Cell reports, 30(11), 3851-3863 (2020-03-19)
Cancer therapy is limited, in part, by lack of specificity. Thus, identifying molecules that are selectively expressed by, and relevant for, cancer cells is of paramount medical importance. Here, we show that peptidyl-prolyl-cis-trans-isomerase (PPIase) FK506-binding protein 10 (FKBP10)-positive cells are

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service